Our partnership Buchanan has worked closely with Alliance Pharma since 2005, supporting its analyst, investor and media relations and outreach to private shareholders.
Growth story A rapidly growing and dividend-paying company, Alliance Pharma has built its product portfolio and international infrastructure through a series of acquisitions. This included a transformational deal in December 2015, which substantially increased the company’s product portfolio and geographic footprint and has been followed by further exciting product acquisitions. The momentum in Alliance Pharma’s business is reflected in its market capitalisation. This was £80m five years ago, but is now more than £500m.